Zip, I don't disagree with you. However, my guess is that most BP's look at this and say "why would we buy a drug company that appears to be shrinking market share, has lost patent exclusivity in NA, still has unanswered questions about drug trial protocol (MO issue), and has just had the entire board and most of senior management taken over by a hedge fund?"
Again, I agree that it SHOULD be worth a whole lot more. I imagine most BP's just need more assurances about the drug before they pull the trigger. But I bet a big part of Sarissa's game plan is to address all of the concerns that BP's would have.
News 
Market Data 
Discover 
